BRPI0410807A - composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica - Google Patents

composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica

Info

Publication number
BRPI0410807A
BRPI0410807A BRPI0410807-8A BRPI0410807A BRPI0410807A BR PI0410807 A BRPI0410807 A BR PI0410807A BR PI0410807 A BRPI0410807 A BR PI0410807A BR PI0410807 A BRPI0410807 A BR PI0410807A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
susceptible
treating
conditions associated
mammal suffering
Prior art date
Application number
BRPI0410807-8A
Other languages
English (en)
Inventor
Alison Green Floyd
Cecilia Carpenter Navy
Gary W Goodson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0410807A publication Critical patent/BRPI0410807A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, E, MéTODO PARA TRATAR UM MAMìFERO SOFRENDO DE OU SUSCEPTìVEL A CONDIçõES ASSOCIADAS COM DOR CEFáLICA". Uma composição farmacêutica, compreendendo um agonista de receptor 5HT~ 1~ ou um seu derivado farmaceuticamente aceitável, em combinação com um NSAID ou seu derivado farmaceuticamente aceitável, em que o agonista de receptor 5HT~ 1~ e NSAID são localizados em zonas distintas em relação entre si, em que cada zona compreende o ingrediente ativo e, opcionalmente, um veículo.
BRPI0410807-8A 2003-06-06 2004-06-02 composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica BRPI0410807A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47648403P 2003-06-06 2003-06-06
US48741303P 2003-07-15 2003-07-15
US49038503P 2003-07-25 2003-07-25
PCT/US2004/017257 WO2004110492A2 (en) 2003-06-06 2004-06-02 Composition comprising triptans and nsaids

Publications (1)

Publication Number Publication Date
BRPI0410807A true BRPI0410807A (pt) 2006-06-27

Family

ID=33556388

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410807-8A BRPI0410807A (pt) 2003-06-06 2004-06-02 composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica

Country Status (8)

Country Link
US (1) US20070184109A1 (pt)
EP (1) EP1633402A2 (pt)
JP (1) JP2006527195A (pt)
KR (1) KR20060015641A (pt)
AU (1) AU2004247076A1 (pt)
BR (1) BRPI0410807A (pt)
CA (1) CA2527368A1 (pt)
WO (1) WO2004110492A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
WO2006035313A1 (en) * 2004-09-29 2006-04-06 Aurobindo Pharma Ltd Solid unit dosage forms of 5-ht1 agonist
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
US20070207200A1 (en) * 2006-03-06 2007-09-06 Pozen Inc. Dosage forms for administering combinations of drugs
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
WO2008124081A2 (en) * 2007-04-04 2008-10-16 Teva Pharmaceutical Industries Ltd. Rapid dissolution of combination products
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
EP2293786B1 (en) 2008-05-21 2014-11-26 Novartis AG Tablettable chewing gums comprising nicotine and a buffering agent
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
AU2009260166B2 (en) * 2008-06-20 2014-10-09 Alphapharm Pty Ltd Pharmaceutical formulation
US20100008986A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Pharmaceutical compositions comprising sumatriptan and naproxen
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
US20120276199A1 (en) * 2011-04-01 2012-11-01 Dr. Reddy's Laboratories Limited Taste masked pharmaceutical formulations
KR102583443B1 (ko) * 2017-05-10 2023-09-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
TR201720429A2 (tr) 2017-12-15 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Flurbi̇profen ve 5-ht1&#8211#&reseptör agoni̇stleri̇ni̇n farmasöti̇k kompozi̇syonlari
CR20210061A (es) * 2018-07-03 2021-03-18 Axsome Therapeutics Inc Composiciones farmacéuticas que comprenden meloxicam
MY198967A (en) * 2019-02-06 2023-10-05 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
GB2595203A (en) * 2020-03-03 2021-11-24 Alkaloid Ad Skopje Formulation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU528098B2 (en) * 1978-11-16 1983-04-14 Beecham Group Plc Analgesic tablet
GR79215B (pt) * 1982-06-07 1984-10-22 Glaxo Group Ltd
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
US4817470A (en) * 1986-06-30 1989-04-04 Zwn Zahnradwerk Neuenstein Gmbh & Co. Gear-shift mechanism for motor-vehicle multi-step transmissions with interruption of traction
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5468504A (en) * 1990-12-21 1995-11-21 Laboratoires Glaxo S.A. Effervescent pharmaceutical compositions
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
KR960701865A (ko) * 1993-04-22 1996-03-28 데이비드 존. 우드 편두통에 사용하는 5-HT1 유사 효능제인 인돌 유도체(Indole Derivatives as 5-HT, -Like Agonists for Use in Migraine)
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5514168A (en) * 1994-05-20 1996-05-07 Friedman; Mark H. Treatment of vascular headache and atypical facial pain
US5618816A (en) * 1995-03-02 1997-04-08 Bristol-Myers Squibb Company Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
WO2000004879A1 (en) * 1998-07-24 2000-02-03 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
ES2194536T3 (es) * 1998-11-13 2003-11-16 Lilly Co Eli Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes

Also Published As

Publication number Publication date
WO2004110492A2 (en) 2004-12-23
KR20060015641A (ko) 2006-02-17
US20070184109A1 (en) 2007-08-09
EP1633402A2 (en) 2006-03-15
CA2527368A1 (en) 2004-12-23
JP2006527195A (ja) 2006-11-30
WO2004110492A3 (en) 2005-02-24
AU2004247076A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
BR9911575A (pt) Heterocìclicos de alquilsulfóxido 4-benzil piperidina e seu uso como antagonistas receptores de nmda seletivas do subtipo
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
NO20060871L (no) Azepinderivater som farmasoytiske midler
SE0202598D0 (sv) Alpha-7 Nicotinic receptor agonists and statins in combination
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BR9916857A (pt) 4 heteroaril diarilaminas
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
TR200100054T2 (tr) Paroksetin metansülfonat
NO20061737L (no) Aminosubstituerte erylamino B2 adrenergiske receptoragonister
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
BRPI0316895B8 (pt) composto, processo para a preparação do composto, composição farmacêutica e uso do composto
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BRPI0507776A (pt) métodos de modular a atividade de citocina; reagentes relacionados
MXPA05010476A (es) Composiciones de inhibidores selectivos de ciclooxigenasa-2 y agonistas de 5-hidroxitripamina1b/1d para el tratamiento y prevencion de migrana.
BR9809071A (pt) Agentes farmacológicos
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]